Fourthly, despite our mediation analyses and recent basic research suggesting that PCSK9 may impact the progression of ischemic HF through pathways beyond LDL-C/CHD, achieving a conclusive understanding requires employing individual GWAS datasets or conducting clinical trials in specific patient cohorts. This evidence concerns the gene PCSK9 and coronary artery disorder.